Abstract Defensins are highly conserved peptides with antimicrobial and immunomodulatory functions. Due to their chemotactic properties on mononuclear cells, including dendritic cells and macrophages, defensins may contribute to granuloma formation in Wegener's granulomatosis (WG). In order to explore whether these peptides might be involved in WG pathogenesis, sera of patients were screened to detect altered defensin levels. For this purpose, serum and EDTA-blood of patients with WG (n = 17; aged 54.8 ± 15.5 years) and age-and sex-matched healthy controls (n = 24; aged 55.5 ± 16.8 years) were collected. Levels of neutrophil a-defensins (human neutrophil peptides, HNP) and b-defensin (hBD) 2 and 3 in serum were measured by ELISA. By this means, WG patients displayed higher serum levels of hBD2 and HNP when compared to controls. Furthermore, serum hBD2 was raised in patients with meningeal granulomas (n = 4) or in those undergoing treatment with cyclophosphamide (n = 4). In order to detect whether increased gene expression in polymorphonuclear cells is responsible for the elevated defensin levels, real-time polymerase chain reaction with gene-specific primers was performed. Expression of specific mRNA in polymorphonuclear cells was observed for HNP only, but did not parallel HNP serum levels, suggesting that degranulation rather than increased gene expression may be responsible for increased HNP serum levels in WG. In conclusion, elevated serum levels of HNP and hBD2 in WG patients suggest a role for both defensins in WG pathogenesis.
Introduction
Defensins initially attracted interest due to their potent antimicrobial functions and highly conserved structure [1] . Consequently, several immunomodulatory functions like chemotactic effects and the ability to induce the production of cytokines have been identified [2, 3] , suggesting that these peptides connect innate and adaptive immune responses [2] . Their importance for autoimmune disorders is supported by the recent finding of modulated defensin expression in patients with systemic lupus erythematosus [4, 5] . Human neutrophil peptides (HNP) stem from the neutrophil granula of leukocytes [6] , while other structurally similar a-defensins are mainly expressed in the small intestine [7, 8] . Among the b-defensins (hBD), distinguished from a-defensins by diverse disulfide bonding, hBD2 and hBD3 are upregulated in response to inflammatory stimuli [9] [10] [11] and are secreted by some epithelial surfaces and blood cells [12, 13] .
Wegener's granulomatosis (WG) is characterized by a granulomatous inflammation with various degrees of vasculitis leading to tissue necrosis with a predilection for the respiratory tract and the kidneys [14] . Antineutrophil cytoplasmatic antibodies (ANCA) directed against proteinase 3 are strongly associated with WG [15] and have been implicated in the pathogenesis of the disease [16] . They activate neutrophil granulocytes and induce the
Section of Rheumatology, Department of Endocrinology, Diabetology and Rheumatology, Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany e-mail: Stefan.Vordenbaeumen@med.uni-duesseldorf.de release of HNP from neutrophils [17] . By the ability to chemoattract monocytes, macrophages, dendritic cells, and T cells [6, 18] , defensins may contribute to granuloma formation in WG [17] . However, reports about defensin serum levels in WG patients are lacking. Therefore, our objective was to evaluate the serum level and expression of HNP, hBD2, and hBD3 in WG patients to further explore whether defensins might play a role in WG pathogenesis.
Materials and methods

Patients and samples
Patients were diagnosed according to ACR criteria [19] . In all consecutive patients, total blood count, creatinine, C-reactive protein (CRP), and ANCA-staining were routinely performed; current and past medications as well as disease manifestations were recorded. Patients were excluded if the presence of infection could not be excluded based on history, physical examination, and urine analysis. Disease activity was determined by the Birmingham vasculitis activity score (BVAS). For performance of defensin ELISA, 10 ml of serum was collected from patients and healthy volunteers and frozen to -20°C prior to the assay. For PCR analysis, 10 ml of EDTA blood was obtained and processed within 2 h. All patients and volunteers gave their full consent. The study was approved by the local ethics committee.
Enzyme-linked immunosorbent assay (ELISA)
Human HNP1-3 ELISA Test Kit (Hycult biotechnology, Uden, The Netherlands) and human b-Defensin 2 and 3 ELISA Kit (Phoenix Pharmaceuticals, Burlingame, California, USA) were applied for measurement of HNP and hBD2 and hBD3, respectively, according to the manufacturer's instructions. Briefly, serum was diluted 1:2,000 in dilution buffer for HNP, 1:100 for hBD2 and undiluted for hBD3 prior to transferring duplicate samples to microtiter plates and initiation of recommended incubation procedures. Absorbance was measured at 450 nm using the Anthos 2001 ELISA reader (anthos Mikrosysteme, Krefeld, Germany).
Semi-quantitative real-time polymerase chain reaction (rtPCR) Polymorphonuclear cells (PMN) were isolated from EDTAblood using Polymorphprep (Axis-Shield, Oslo, Norway), mRNA was isolated with Rneasy Mini Kit (Qiagen, Hilden, Germany), and reverse transcription was performed using QantiTect Reverse Transcription (Qiagen) according to the manufacturer's instructions. Polymerase chain reaction (PCR) with real-time measurement of fluorescence was carried out on the 7300 Real-time PCR system (Applied Biosystems, Foster City, CA, USA) with 0.3 lM genespecific, exon-spanning primers for HNP (fw: 
Results
Patient characteristics
Seventeen consecutive patients with WG were aged 54.8 ± 15.5 years (mean ± SD; 47.1% female). Healthy controls (n = 24) were aged 55.5 ± 16.8 years (mean ± SD; 50% female). There were no correlations of measured parameters to sex, age, laboratory values or BVAS. Diseases extend, laboratory values, and treatment at the time of the study are summarized in table 1.
Defensin measurements
In order to determine serum levels of defensins, ELISA for hBD2, hBD3, and HNP was performed on samples of patients and healthy controls. HBD2 and HNP, but not hBD3, were elevated in patients with WG as opposed to healthy controls (Fig. 1) . To determine whether defensin levels varied with respect to the disease state, serum levels were compared to clinical data and laboratory values. Thereby, hBD2 was found to be higher in patients with meningeal involvement (n = 4; Fig. 2) , evidenced by the presence of proliferations on magnetic resonance imaging. Furthermore, patients undergoing treatment with cyclophosphamide displayed superior levels of serum HNP (n = 4; Fig. 2 ). Next, we assessed whether PMN could be the source of defensins in WG patients. For this purpose, we performed real-time PCR with gene-specific primers for the defensins studied. Only HNP-mRNA was detectable, but did not parallel serum HNP measurements. Values between patients and controls were rather equal.
Discussion
ANCA-mediated release of a-defensins might contribute to granuloma formation due to chemotactic properties on monocytes, macrophages, dendritic cells, and T cells [6, 17] . Similarly, hBD2 and hBD3 chemoattract macrophages and monocytes [18] . Interestingly, high a-defensin levels have been reported in the bronchoalveolar lavage fluid and plasma of one WG patient previously [20] . Furthermore, other vasculitic diseases, like microscopic polyangiitis [21] and Creatinine (mg/dl) 1.5 ± 1.0
Disease activity parameters (mean ± SD) BVAS 12.6 ± 14.6
Organ involvement (n (%)) Significant results as determined by Mann-Whitney U-test are indicated cutaneous vasculitis [22] , were associated with increased a-defensins and hBD2 expression, respectively. The present study demonstrates elevated serum values of HNP and hBD2 in WG patients when compared to healthy controls. Meningeal granulomas and cyclophosphamid treatment, which might be found more frequently in sicker patients, were associated with modulated hBD2 and HNP serum levels, respectively. Although hampered by the small patient number, these findings support the notion that defensins might be involved in WG pathogenesis and are an interesting target for future research as novel therapeutic options may arise. Neutrophile granula of leukocytes are the main source of human neutrophile peptides (a-defensin 1-4) [6] . Interestingly, no correlation of HNP serum levels to the leukocyte count or to HNP-mRNA copy-numbers were found. Thus, we speculate that degranulation of neutrophile granulocytes rather than increased neutrophile numbers or increased HNP gene expression is responsible for elevated a-defensin levels in WG patients. Beta-defensins are expressed in various tissues, which might contribute to b-defensin serum levels [1] . Based on our observations, PMN are unlikely to be responsible for b-defensin production, because no specific mRNA was found.
Although the study served to address our objectives, the small patient number and relatively high standard deviations may be regarded as drawbacks to this study.
Conclusions
To the best of our knowledge, this is the first study to systematically evaluate serum defensin levels in WG. Our results further implicate a role for HNP and hBD2 in WG pathogenesis. Additional studies in this interesting field are needed.
